<DOC>
	<DOCNO>NCT02740231</DOCNO>
	<brief_summary>Osteoarthritis ( OA ) common joint disease affect million people around world , unfortunately cure . Among exist therapy , viscosupplementation , i.e. , injection hyaluronic acid joint , establish place symptomatic treatment knee OA . The present Phase IIb/III aim assess safety efficacy JTA-004 organize two phase . With result obtain first phase best dose JTA-004 determine , efficacy select dose confirm second phase .</brief_summary>
	<brief_title>A Study Visco-antalgic Intra-articular Administration Symptomatic Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Ability provide write , date , sign informed consent prior study related procedure , understand comply study requirement Ambulatory Diagnosed primary knee osteoarthritis , fulfil follow American College Rheumatology ( ACR ) criteria target knee : Pain â‰¥ 40 mm 0100 mm VAS 3 day precede date screen visit Morning stiffness exceed 30 minute KellgrenLawrence grade II III Insufficient / fail response analgesic / NSAIDs No physical therapy knee , knee brace entire duration study Current symptom and/or sign related disease study : Isolated symptomatic femoropatellar OA target knee History trauma surgery arthroscopy target knee within 6 month inclusion Concomitant inflammatory disease condition affect joint ( e.g. , rheumatoid arthritis , septic arthritis , inflammatory joint disease , metabolic bone disease , psoriasis , gout , microcrystalline arthropathies/chondrocalcinosis , Paget 's disease ) Any musculoskeletal condition ( hip osteoarthritis , amputation , neurologic disorder ) would impede measurement efficacy target knee Target knee prosthesis plan within 12 month Screening Visit Current previous diagnosis , sign and/or symptom : Uncontrolled diabetes mellitus , endstage hepatic renal disease Current ( within last 5 year prior enter study ) history solid haematological neoplasia bone marrow transplantation ( except basal cell carcinoma completely excise squamous cell carcinoma ) Other severe acute chronic medical psychiatric condition predisposition laboratory abnormality , judge Investigator Current past history coagulation disorder , judge Investigator Hypersensitivity component HAbased injection product History hypersensitivity human biological material include blood blood derive product , potential excipients residue manufactoring process document clinically laboratory test Hypersensitivity avian proteins Life expectancy le 6 month Current previous treatment : Participation another clinical study within 6 month prior Screening Patients previously treat JTA004 Treatment : Within 6 month prior Screening : intraarticular hyaluronic acid injection target knee Within 2 month prior Screening : intraarticular glucocorticoid target knee Current chemo , radio immunocancertherapy immunosuppressive therapy Current ( within 6 month prior Screening ) illicit drug abuse Safety aspects concern female subject childbearing potential : Females pregnant , lactate woman childbearing potential ( last menstrual bleeding le 12 month ago ) unwilling use medically acceptable contraception , woman childbearing potential unwilling perform pregnancy test administration study treatment . Other exclusion criterion : Body Mass Index ( BMI ) 35 kg/m2 great</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>viscosupplement</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>knee</keyword>
	<keyword>intra-articular injection</keyword>
	<keyword>arthritis</keyword>
	<keyword>degenerative</keyword>
</DOC>